Paper Details

  1. Home
  2. Paper Details

Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Author: AustermannJudith, Bar-OrAmit, BrassatDavid, BreuerJohanna, BuschKarin B, CampbellGraham R, EschbornMelanie, EveslageMaria, FreiseNicole, GlanderShirin, GrossCatharina C, HeroldMartin, HundehegePetra, JanoschkaClaudia, KlotzLuisa, LiebmannMarie, LindnerMaren, LoserKarin, MahadDon J, MeuthSven G, NebelGiulia, PignoletBéatrice, PosevitzVilmos, RothJohannes, Schneider-HohendorfTilman, Schulte-MecklenbeckAndreas, SchwabNicholas, StollMonika, Torres GarridoBelén, TurnerTimothy, WiendlHeinz, WirthTimo

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Teriflunomide is a drug that inhibits dihydroorotate dehydrogenase (DHODH), an enzyme involved in the production of pyrimidines, essential building blocks for DNA and RNA. This study investigated the effects of teriflunomide on T cells, a type of immune cell involved in autoimmune diseases like multiple sclerosis (MS). The study found that teriflunomide preferentially suppressed the proliferation of high-affinity T cells, likely due to its effect on T cell metabolism. These findings suggest that teriflunomide may be particularly effective in targeting autoreactive T cells, which are responsible for driving autoimmune responses.
Paper Details　
Original Abstract of the Article :
Interference with immune cell proliferation represents a successful treatment strategy in T cell-mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis (MS). One prominent example is pharmacological inhibition of dihydroorotate dehydrogenase (DHODH), which mediates de novo ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1126/scitranslmed.aao5563

データ提供：米国国立医学図書館（NLM）

Teriflunomide: A New Oasis in the Desert of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease that can feel like a relentless desert of neurological challenges. This study investigates the mechanism of action of teriflunomide, a medication used to treat MS, focusing on its effects on T cell mitochondrial respiration. The researchers examined the impact of teriflunomide on T cell metabolism, particularly oxidative phosphorylation (OXPHOS), and its role in regulating T cell function.

Teriflunomide: A Potential Path to Moderating Immune Response

The study revealed that teriflunomide treatment modulates T cell mitochondrial respiration, with affinity-dependent effects on high-affinity T cells. Teriflunomide preferentially suppresses the proliferation of high-affinity T cells, potentially contributing to its efficacy in treating MS. The researchers suggest that teriflunomide may help to restore an altered T cell receptor repertoire in autoimmune conditions, potentially leading to improved disease control.

A Camel's Perspective: Exploring New Pathways for MS Treatment

The desert of MS can be a long and challenging journey. This study sheds light on a potential new oasis in the form of teriflunomide, offering a promising mechanism of action that targets T cell metabolism. It's exciting to see new research exploring novel treatment pathways for this complex condition.

Dr. Camel's Conclusion

This research provides valuable insights into the mechanism of action of teriflunomide, a medication used to treat MS. The study's findings suggest that teriflunomide modulates T cell mitochondrial respiration, potentially contributing to its efficacy in managing the disease. It's exciting to see new research exploring novel treatment pathways for MS, offering hope for those navigating the challenging desert of this condition.

Date :
  1. Date Completed 2020-06-26
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31043571

DOI: Digital Object Identifier

10.1126/scitranslmed.aao5563

Related Literature

Article Analysis
・Effects of teriflunomide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.